Loading patent…
AssigneesShi-Lung Lin, David TS Wu
InventorsShi-Lung LIN, Yi-Wen LIN
Estimating the term…
This invention relates to a composition and its use for formulating nucleic acid-based drugs/vaccines with sugar alcohol compositions into complexes for both in-vitro and in-vivo delivery. Particularly, the present invention includes the ingredients and processes necessary for formulating therapeutic and pharmaceutical nucleic acid compositions, such as miRNA, microRNA precursors, shRNAs, siRNAs, ribozymes, antisense RNAs/DNAs, RNA-DNA hybrids and DNA vectors/vaccines, with glycylated sugar alcohols/sugars into delivery complexes, which can then be absorbed by cells in vivo and in vitro via active endocytosis. Also, the present invention discloses that chemical compounds containing sugar alcohol- and/or sugar-like structures can protect nucleic acids, in particular miRNAs, shRNAs, siRNAs and ribozymes, from degradation in vivo as well as in vitro. Therefore, the present invention is also a formula and method for preserving the structural integrity and functional efficacy of these nucleic acid-based drugs and/or vaccines in vivo and in vitro.
A composition and its use for formulating nucleic acid compositions with sugars and sugar alcohols into stable complexes for both in-vitro and in-vivo delivery into mammalian cells, comprising:
A formulation composition for delivering nucleic acids into cells in vitro as well as in vivo, comprising a mixture of at least a sugar or sugar alcohol with hydroxyl group, at least a amino acid with a structure of glycyl group, and at least a nucleic acid composition, wherein said mixture further comprises at least one glycylated sugar or glycylated sugar alcohol which interacts with said nucleic acid composition via ionic or electrostatic affinity and forms a delivery complex at a pH value below 8.0.
Dependencies are inferred from the claim text.